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Abstract
Traumatic brain injury (TBI) causes death and disability in the United States and
around the world. The traumatic insult causes the mechanical injury of the brain and
primary cellular death. While a comprehensive pathological mechanism of TBI is still
lacking, the focus of the TBI research is concentrated on understanding the pathophysiology and developing suitable therapeutic approaches. Given the complexities
in pathophysiology involving interconnected immunologic, inflammatory, and neurological cascades occurring after TBI, the therapies directed to a single mechanism fail
in the clinical trials. This has led to the development of the paradigm of a combination
therapeutic approach against TBI. While there are no drugs available for the treatment of TBI, stem cell therapy has shown promising results in preclinical studies. But,
the success of the therapy depends on the survival of the stem cells, which are limited by several factors including route of administration, health of the administered
cells, and inflammatory microenvironment of the injured brain. Reducing the inflammation prior to cell administration may provide a better outcome of cell therapy following TBI. This review is focused on different therapeutic approaches of TBI and the
present status of the clinical trials.
KEYWORDS

clinical trials, combination treatment, stem cells, traumatic brain injury

1 | I NTRO D U C TI O N

and released from the emergency department. 2 Long-term disability
depends on the severity of the TBI,3 the presence of diffuse axonal

The Centers for Disease Control and Prevention defines a traumatic

injury on imaging,4 and the intensity of neurorehabilitation.5 Further,

brain injury (TBI) as a disruption in normal brain function as a result

recovery may take an extended period of time6 and the patient

of any blow to the head.1 It is a major health concern in the United

may be left with neurobehavioral deficits including mental health

States and around the world. According to the Health United States

disorders such as depression, anxiety or psychotic disorders, cog-

Report 2016, 2.8 million people in this country sustain this injury

nitive disorders related to executive functioning, and aggression.7

annually, and it is estimated that of these, ~50 000 die, ~282 000

In a prospective study that followed TBI patients for up to 1 year,

are hospitalized, and the remaining 2.5 million (or 89%) are treated

the distribution of mild, moderate, and severe TBI was comparable

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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to what is observed in the real-world population with 49% having

the fathers of modern neuroscience, stated in his treatise on neural

mild TBI, 34% having moderate TBI, and 17% having a severe injury.

development and regeneration “…once development was ended, the

About half of the study population did not return to their previous

founts of growth and regeneration of the axons and dendrites dried

work after 1 year, and ~28% never returned to work of any kind.8

up irrevocably. In the adult centers the nerve paths are something

Also, long-term disability is seen occasionally even in those with mild

fixed, ended and immutable. Everything must die, nothing may be

9

TBI. Thorough reviews of TBI epidemiology have recently been

regenerated. It is for the science of the future to change, if possi-

published.10,11

ble, this harsh decree.”20 When we consider additional factors such

Thus, while TBI is a significant public health problem, unfortu-

as the confined space within the skull that contributes to increased

nately there is no single therapy that has proved efficacious in its

intracranial pressure as edema develops and the blood-brain barrier

treatment. Similar to the situation with other brain injuries (such as

(BBB), which can make therapeutic access to the brain difficult, the

the failure of neuroprotective glutamate receptor antagonists and

task of repairing the brain after TBI may seem insurmountable.

antioxidant treatments in clinical trials for stroke12,13) and neuro-

The pathophysiology of TBI occurs in two main phases—the pri-

degenerative diseases, there have been myriad-positive preclinical

mary insult and the secondary sequelae. The primary insult is the ini-

studies in TBI models and all of these promising therapies have failed

tial blow to the head. It can be a penetrating wound or a closed-head

in clinical trials. Various reasons have been advanced for these fail-

injury. The nature of the injury can be focal, involving a very circum-

ures, including, but not limited to, differences in brain anatomy and

scribed area of the brain, or it can be more diffuse causing widespread

physiology between rodents and humans, inadequate animal mod-

axonal injury. Then, there is the special case of the coup-counter-

els, failure to test the treatment in a clinically relevant way coupled

coup injury as the brain impacts the skull in two sites on opposite

with failure to remain faithful to the preclinical testing parameters in

sides of the brain; this is observed with trauma that involves deceler-

the clinical trials, underpowered studies, heterogeneity of TBI injury,

ation of the head. Depending on the nature of the trauma, neurons,

and insensitive outcome measures in both preclinical and clinical

astrocytes, and oligodendrocytes may be destroyed, bleeding may

studies. There is no dearth of discussions in the literature identifying

occur, axons may be severed, and a contusion may form. 21 The im-

these shortcomings in the therapeutic development and testing of

mediate pathological consequences of these injuries are similar to

potential new treatments for TBI.14-18

those observed with cerebral ischemia—excitotoxicity, changes in

What we are left with for treatments is a general approach that

ion flux (Ca++, Na+, and K+) across the cell membrane, loss of ATP, lac-

is akin to crisis management. According to the current Brain Trauma

tate production, induction of cortical spreading depression, cytokine

Foundation Guidelines, based on the best available medical evidence

production, and loss of barrier function at the BBB. 22-24

for the management of severe TBI, it is imperative to provide ad-

The severity of the initial blow and the immediate pathophysio-

equate nutrition, support breathing by tracheostomy, and perform

logic changes that occur determines the severity of any subsequent

a large decompressive craniectomy.19 The underlying problems for

secondary degenerative processes. In the acute period, neurons and

developing an effective treatment for TBI are 2-fold. First, the injury

axons continue to die, and there is damage to the vascular endothe-

can be unique to the patient, depending on the type of TBI and the

lium; this, in turn, allows blood components to leak into the brain pa-

region of the brain affected. Second, once that injury occurs, a com-

renchyma, including peripheral immune cells, which then contribute

plicated neurodegenerative cascade is triggered; resolving any one

to the pro-inflammatory environment. Astrocytes swell and tissue

of these pathological processes is not enough to prevent or termi-

edema occurs. If edema is not controlled, intracranial pressure in-

nate the others. In this review, we will discuss the pathophysiology

creases, which can lead to compression of arteries and decreased

of TBI with emphasis on immune and inflammatory function. We

cerebral blood flow; cerebral ischemia commonly occurs under these

will also discuss the evidence for the development of a mesenchy-

conditions leading to a vicious cycle of increasing edema, increasing

mal stem cell (MSC)-based treatment that can suppress immune and

intracranial pressure, and increased ischemia that can lead to death.

inflammatory/degenerative cascades and provide neuroprotection.

2 | PATH O PH YS I O LO G Y O F TB I

3 | I N FL A M M ATI O N I N TB I
The main architects of the local inflammation at the site of injury

The pathophysiologic mechanisms of TBI are poorly understood as

are the microglia. Once a TBI has occurred, it is the microglia that

the anatomy of the brain is uniquely complex with multiple cell types

proliferate and migrate to the site of the damage. As these microglia

(neurons, astrocytes, oligodendrocytes, and microglia) and multi-

work to remove the cellular debris at the lesion site, they produce

ple subtypes of these cells. While we now know that neural stem

cytokines and chemokines that activate pattern recognition recep-

cells (NSC) exist within the adult brain and some degree of axonal,

tors to bind damage-associated molecular patterns, and attract and

dendritic, and synaptic plasticity occurs, we have yet to fully exploit

polarize peripheral immune cells. The first peripheral immune cells

the brain's regenerative capacity to repair an injury. Add to this the

into the damaged tissue are neutrophils25 followed 24-48 hours later

complicated neuronal networks throughout the brain and neural re-

by monocytes or macrophage, and T cells all of which are releasing

pair is a daunting task. Ramon Y Cajal, widely regarded as one of

cytokines and chemokines. Once the peripheral immune cells have

618

|

WILLING et al.

established a strong pro-inflammatory response in the brain in the

and neurobehavioral symptoms that may arise.43 With the occurrence

acute to subacute stage of TBI, then tissue damage is likely to be ex-

of so many interconnected neuro-immune-inflammatory pathologic

acerbated. Further, the T cells may become activated through antigen

cascades engaged after TBI, it is not surprising that therapies target-

presentation by microglia and macrophage, mobilizing the adaptive

ing one specific degenerative pathway have failed to demonstrate

immune system26 and potentially leading to autoimmunity. 26,27

efficacy in clinical trials. Drug interventions that have been studied

In addition to local neuroinflammatory processes within the brain

can generally be categorized by their therapeutic target. One class of

after TBI, systemic immune and inflammatory processes are also im-

drugs are those that prevent calcium ion flux. An example of such an

pacted and have recently been reviewed.28,29 Peripheral immune cells

approach is the calcium channel blocker, Nimodipine, which showed

are mobilized from the bone marrow,30 thymus,31 and spleen31 early

promising effects in rodents but exhibited only a small effect on TBI

after the TBI. While there is a brief recovery in thymocytes and classi-

patients.44,45 Disruption of intracellular calcium signaling may also

cal monocytes in thymus and spleen within the first 2 weeks postinjury,

improve outcome after TBI. Cyclosporin is a T-cell immunosuppres-

over time these cell populations decline again and may be responsible

sant that acts by binding to cyclophilin; the cyclosporine-cyclophilin

for the post-TBI immune suppression that is observed in patients.29,31

complex binds to calcineurin preventing dephosphorylation of NFAT,

Also implicated in the peripheral immune response and long-term

translocation to the nucleus, and increased transcription of interleu-

immune suppression is both the activation of the hypothalamus-pi-

kin (IL) 2.46 In the absence of cyclosporine, calcineurin is regulated by

tuitary-adrenal axis, through the release of glucocorticoids and the

calcium and calmodulin. Cyclosporin prevents calcium ion transport

sympathetic nervous system, through release of catecholamines.29,32

into the mitochondria in animal models but not in TBI patients.47

Ideally, inflammation will be a self-limiting process. There are

There are also a number of studies that have targeted excito-

endogenously formed products of arachidonic acid metabolism

toxicity, specifically glutamate release and overstimulation of the

that actively inhibit pro-inflammatory responses.33 These include

NMDA receptor. For example, Selfotel is a NMDA antagonist and

the lipoxins, resolvins, protectins, and maresins, which decrease

the first glutamate antagonist to enter into Phase III clinical trial.

pro-inflammatory cytokine secretion,

34

alter migratory signals for

This trial was discontinued because of high mortality and a failure to

peripheral immune cells,35 and stimulate neuroprotective and tissue

improve Glasgow Outcome Score.48 The results from clinical stud-

regeneration processes.

36

There has been very little research on

ies of other NMDA receptor antagonists also failed to demonstrate

these resolving mediators in TBI, but administering the lipoxin, LXA4,

any efficacy of treatment.49 While not a true antagonist, magnesium

into the lateral ventricles 10 minutes after a TBI induced by weight

blocks the NMDA receptor calcium channel. Increasing available

drop, reduced pro-inflammation, BBB disruption, and lesion size.34

magnesium also had no effect on TBI outcome.50

Further, its receptor, ALX/FPR2, is upregulated in astrocytes.

37

Another approach has been to target oxidative stress produced

Unfortunately, in many instances inflammation may not resolve

by oxygen radical formation and lipid peroxidation. The lipid per-

and becomes chronic.38 In the aged brain, there is increased recruit-

oxidation inhibitor, Tirilazad mesylate, which is an approved drug

ment of peripheral macrophage into the TBI brain.39 In addition to

in Europe to treat aneurismal subarachnoid hemorrhage, showed

cellular infiltration of pro-inflammatory immune cells after TBI, sus-

promising neuro- and vaso-protective responses in animal models

tained complement C3 activation leads to chronic inflammation by

of moderate-to-severe TBI but failed to show improvement over

activating microglia and astrocytes in the region around the initial

placebo control in Phase III clinical trials involving human TBI pa-

lesion and contributes to further neuronal loss 30 days post-TBI.40

tients.51,52 Pegylated superoxide dismutase, a free radical scavenger,

Using a combination of magnetic resonance imaging, magnetic reso-

was found to be effective in preventing secondary injury in preclin-

nance spectroscopy, and positron emission tomography in a rat lateral

ical and Phase I clinical studies but failed to show reduction in mor-

fluid percussion model, inflammation was shown to be present still

tality or improve neurologic outcome in Phase III trials.53,54 Another

41

6 months post-TBI. Even 12 months after a controlled cortical impact

antioxidant that may be promising is N-acetylcysteine. When admin-

in mouse, there is increased immunolabeling for IBA1 (microglia) and

istered to patients within 24 hours of mild TBI, symptoms were sig-

glial fibrillary acidic protein (GFAP).42 What's more, this chronic inflam-

nificantly better compared to a placebo-controlled group.55

mation is associated with continued behavioral deficits.

Another target that has been examined is the treatment of
inflammation with corticosteroids, statins,56 cannabinoids, and

4 | E X PE R I M E NTA L PH A R M AC EU TI C
TR E ATM E NT S FO R TB I

bradykinin B2 receptor antagonists.50 In addition, the gonadal hormones, estrogen and progesterone, both showed promising results
in preclinical studies but failed to show beneficial effects in clinical
trials.57-59
The more recent approach has been to search for potential ther-

4.1 | Pharmaceuticals

apies that target more than one pathway. One such strategy is to use
a pharmacologic that interacts with multiple receptor types, which,
thereby, produces more than one effect. For example, sigma recep-

The focus of current pharmacological interventions after TBI is to

tor agonists selective for either sigma 1 (σ1) or σ2 receptors (or both)

manage level of consciousness, neuropsychiatric, neurocognitive,

have both neuroprotective and anti-inflammatory effects in rodent

|
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models of stroke.60 More recently, σ1-selective agonists have been
shown to decrease neuroinflammation,
are neuroprotective after TBI.

62

61

while σ2-selective agonists

619

endothelial growth factor (VEGF), nerve growth factor (NGF), and
regenerate BBB and neuronal and glial tissues.78-81 MSCs also modulated inflammation by inhibiting interleukin six (IL-6) and IL1-β and
enhancing IL-10.82 The anti-inflammatory effect of MSC was re-

4.2 | Combination drug treatment regimens for TBI

ported in a study involving combined administration of MSC and
NSC that led to increased recovery from stroke-induced cerebral
damage in rats as compared to MSC or NSC alone.83 Early studies

In an effort to increase treatment efficacy, multiple drug combina-

demonstrated that intravenous,84 intraarterial,85 and intracerebral

tions have been administered together to target multiple neurode-

86

generative pathways. Based on reported success in the treatment

cal outcome after TBI. Other methods of MSC delivery that have

of HIV/AIDS with HAART,63 recently a combination drug therapy

been used since include intranasal,87-89 intrathecal,90 and intracis-

combining vitamin D3,

ternal.91 The postulated mechanism of repair in these early studies

progesterone, omega 3 fatty acids, and glutamine administration

was transdifferentiation of the cells into neural cells. A number of

for the first 72 hours for TBI patients with a poor prognosis; all pa-

studies were able to demonstrate that some of the transplanted

tients improved beyond original expectations. However, these case

MSCs expressed neuronal and astrocytic markers in vivo, but few

studies included only three patients, there were no controls, and a

cells survived.84,85,92-94 The results of in vitro studies were more

larger study has not been performed to validate these observations.

positive95; however, the transformation from MSC to mature neuron

Another example of a combination of drug therapy is the progester-

occurred within hours,96 was reversible when the initiating stimuli

one and 1,25-dihydroxyvitamin D3 combination, which was effec-

were removed, and occurred in the presence of protein synthesis

tive in reducing neuroinflammation as compared to treatment with

inhibition.97 It has been suggested that the “transdifferentiation” of

the drugs separately.65,66

MSCs into neurons requires MSCs to be in a toxic, stressful environ-

was designed for the treatment of TBI

64

administration of these cells improved motor and neurologi-

ment.96,97 However, the ultimate proof that the cells transdifferen-

5 | C E LL TH E R A PY I N TB I

tiate into neurons is still lacking; these “neurons” have never been
shown to produce an action potential.98
In the ensuing years, several other putative mechanisms of re-

A number of different cell types have been examined as potential

pair for these cells have been studied. Thus, it has been suggested

therapeutics for TBI. The first studies in the field focused on replac-

that MSCs may induce brain repair through the production of tro-

ing neurons in order to rebuild the neural circuitry. The earliest cells

phic factors or stimulating release of trophic factors from endoge-

examined were already postmitotic neurons,67-69 and there was vari-

nous cells.99-101 These paracrine mechanisms of repair have recently

able therapeutic success. Gradually, these studies were replaced by

been reviewed in some detail.102-104 More recently, MSC-derived

studies using stem cells. In a mouse model, NSC survived, differen-

exosomes have been examined as the paracrine source of neuro-

tiated, migrated to the lesion site, and improved motor and cogni-

protection and anti-inflammation. These exosomes improved cogni-

tive function after TBI.70 Also, embryonic stem cells were shown to

tive function and reduced inflammation as determined by decreased

improve functional outcome after TBI in rodents, but tumors also

IL-1 and increased IL-10 in the brain after TBI.105 Later studies are

71

Later studies involved predifferentiating stem cells into

consistent with these results.106,107 MSC-derived exosomes have

more lineage-restricted precursors in order to reduce the likelihood

also been tested in porcine model of TBI coupled with hemorrhagic

of tumorigenesis.72,73 In an effort to reduce reliance on embryonic or

shock; consistent with the rodent data, the pigs had fewer cognitive

fetal tissue, there have been a number of studies more recently fo-

deficits as determined with a neurological severity score and recov-

cused on induced pluripotent stem cells derived from adult somatic

ered faster than nontreated pigs.108 There is also evidence for MSC

formed.

74-76

cells.

inducing immune suppression109,110 and anti-inflammation106,111-113;

In addition to these embryonic and NSC for which there are di-

stimulating neurogenesis88,114,115 and angiogenesis107,116,117; activat-

rect developmental pathways to produce neurons, astrocytes, and

ing survival pathways118 and inhibiting apoptotic pathways101,119;

oligodendrocytes, another source of stem cells that has received

and enhancing neuroplasticity through neurite outgrowth120,121 and

a great deal of attention is MSCs. Originally, MSCs were isolated

synaptogenesis.78,107

from bone marrow where they support hematopoiesis. However, it
has become clear that MSCs reside in many tissues in the body,77
which may explain why they appear to be efficacious for treating

5.1 | Clinical translation of cell therapy for TBI

so many different injuries and diseases. Because of their pleiotropic characteristics, these cells have significant therapeutic potential

As described in the previous section, many different approaches

for various diseases including TBI. Following administration, MSCs

have shown promise for treating TBI-induced pathologies and stimu-

have shown to penetrate the BBB, migrate to the site of injury, and

lating tissue regeneration in animal models. However, none of these

secrete several growth factors including brain-derived neurotrophic

have thus far translated into therapeutic benefit in human patients

factor (BDNF), glial-derived neurotrophic factor (GDNF), vascular

and the early clinical trials have not used pure MSC. Table 1 shows

|

the current comprehensive status of clinical trials of stem cell ther-

200

47

61

25

55

apy for TBI. The earliest clinical studies reported in the literature
24

Enrollment
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used bone marrow-derived mononuclear cells (BMMNCs), which
is a heterogeneous mixture of immune cells and stem cells including MSCs. The first major cell therapy trials for TBI using BMMNCs

Phase 1|Phase 2

study from the same research group, the TBI-induced increase in intracranial pressure was reduced in the cell treatment group.123
There are also clinical trials of BMMNCs in the adults with severe

Procedure: Microcannula Harvest
Adipose|Device: Centricyte 1000|Procedure:
Sterile Normal Saline IV deployment AD-cSVF

TBI. In this population, treatment with BMMNCs resulted in struc-

Enrolling by invitation

Phase 1|Phase 2
Biological: autologous bone marrow mononuclear
cells|Other: Placebo Infusion
Active, not recruiting

Phase 2
Biological: SB623 cells Procedure: Sham Control
Completed

Phase 1|Phase 2
Biological: autologous bone marrow mononuclear
cells
Completed

permeability and neuroinflammation after TBI. In a second pediatric

tural preservation of the corpus callosum and corticospinal tract and
these changes were correlated to neurocognitive outcomes; in addition, there was a reduction in the pro-inflammatory cytokine response to injury (NCT01575470).124 A Phase 2 (NCT02525432) and
Phase IIb (NCT02416492) follow-up studies are currently underway.
Of the currently registered clinical trials specifically investigating MSCs, there are two. Hope Bioscience has a safety and efficacy
clinical trial of its adipose-derived MSCs. In another clinical trial
(NCT02416492), the safety and efficacy of San Bio's proprietary
adult bone marrow-derived MSCs genetically modified to express
the intracellular domain of human Notch-1 to treat chronic TBI.
Clinical trial of these cells in stroke patients demonstrated that the
cells were safe and induced significant motor function improvement
in adults according to European Stroke Scale, the NIH Stroke Scale,
and the Fugl-Meyer scale.125

5.2 | Potential of MSC and anti-inflammatory
combination treatments for TBI

cades, the brain environment post-TBI is a hostile environment for
Use of adipose-derived stem/stromal cells in
concussion and traumatic brain injuries

pediatric autologous bone marrow mononuclear
cells for severe traumatic brain injury

A study of modified stem cells in TBI

Because of inflammation and other ongoing neurodegenerative casTreatment of severe adult traumatic brain injury
using bone marrow mononuclear cells

Phase 2
Biological: Placebo Infusion Biological:
Autologous BMMNC Infusion
Enrolling by invitation
Autologous stem cell study for adult TBI (Phase 2b)

Phase 1 Phase 2
Drug: HB-adMSC
Not yet recruiting
A clinical trial to determine the safety and efficacy
of hope biosciences autologous mesenchymal stem
cell therapy for the treatment of traumatic brain
injury and hypoxic-ischemic encephalopathy

Status
Title

preclinical studies and Phase 1 clinical trial, treatment reduced BBB

transplanted cells. Without some adjunctive treatment, cell survival
is limited. For NSC and neurons, where the cells are needed to rebuild neural circuitry, survival is critical. For MSCs, whether survival
is necessary depends on where and how the cells are having their
effects. The immune-suppressive effects of the cells are systemic, so
delivery to the brain is not critical.113,126,127 Their anti-inflammatory
effects are both systemic and local within the brain, so some cells
need to enter the brain.111,112 These functions have led to studies
of these cells as cotransplants to enhance the survival of other cells;
an example from the spinal cord injury literature demonstrated that
MSCs cotransplanted with NSC in injured spinal cord resulted in
increased survival of the NSC.128 While MSCs do have anti-inflammatory properties, the noxious environment may decrease their

NCT02959294

NCT01851083

NCT02416492

NCT01575470

NCT02525432

NCT04063215

survival as well,129 which may limit their neuroprotective effects. To
NCT number

Current status of cell therapy clinical trials of traumatic brain injury (TBI)

Interventions

Phases

were conducted on children by Cox and colleagues in 2011.122 In the

TA B L E 1

620

deal with the problem of a toxic, degenerative environment in the
brain post-TBI, investigators have adopted multiple approaches to
enhance cell survival.
One approach has been to delay transplantation so that the
pathophysiology can stabilize; for example, in a study comparing

|
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MSCs with MSCs in a scaffold,130 MSCs were administered two

resulted in faster improvement in the forelimb placing and balance

months post-TBI so that regenerative and repair physiologic pro-

beam tests compared to the no treatment TBI group and the cell-

cesses would dominant in the parenchyma around the TBI lesion.

only group. Insulin-like growth factor-1 known to have a crucial role

Another approach has been to administer a drug treatment along

in MSC proliferation and putative differentiation to neuronal cells.144

with the cells or prior to cell transplantation. For example, Mahmood

This approach has shown to improve cell injury and motor activity of

and associates administered MSCs intravenously 24 hours after

injured rats and improved metabolic and nutritional outcomes fol-

TBI.131,132 At the same time, statin treatment was started and con-

lowing TBI.145,146 However, even growth factor delivery directly into

tinued for 14 days. Combination treatment with either atorvasta-

the central nervous system (CNS) can lead to adverse effects. In a

tin or simvastatin improved recovery on the modified Neurological

recent review of NGF trials for CNS diseases, the authors point out

Severity Score (mNSS). In another study, investigators combined an

significant adverse effects such as pain and weight loss led to the

early (1 hour post-TBI) injection of the β adrenergic antagonist, pro-

discontinuation of the studies.142,147

pranolol, with an intravenous administration of MSCs at 72 hours

The most common procedure for combining a growth factor

post-TBI.133 The underlying premise of the study was that propran-

treatment with the delivery of MSCs has been to transfect the cells

olol decreases the TBI-induced Sympathetic Nervous System hy-

with specific growth factors. For example, overexpressing FGF21 in

peractivity; this decreased activity then helps to maintain cerebral

MSC resulted in improved performance on the Morris water maze,

perfusion, thereby decreasing post-TBI ischemia and cell death. The

increased hippocampal neurogenesis and dendritic outgrowth.148

MSCs were administered to manage the secondary inflammatory

Other investigators have focused on the neurotrophins. Wu and

state. Unfortunately, the combined effects of propranolol and MSCs

associates overexpressed NT3 in MSCs and observed decreased

were not synergistic or additive; favorable outcomes (decreased

glial activation, a smaller brain lesion, and decreased edema in the

serum norepinephrine, BBB permeability, microglial activation, cog-

brain,149 while a number of investigators have focused on increas-

nitive function) could be achieved solely by the MSCs. In another

ing BDNF expression in the cells, essentially improving functional

study, investigators administered a calpain inhibitor 30 minutes after

outcome.150,151

134

TBI and then transplanted the MSCs at 24 hours post-TBI.

There

More recently, transplanting MSCs with a bioactive scaffold or

were significant decreases in pro-inflammatory cytokines around

biomaterial that secretes growth factors has been used to enhance

the lesion, increased survival of the MSCs, and improvements on the

survival, migration, and differentiation of transplanted cells.152 In

mNSS.

one version of a scaffold, Bhang and associates suspended MSCs

We have taken a similar approach, but instead of modifying

in a fibrin gel laced with FGF2.153 The MSCs in the fibrin glue with

sympathetic activity in conjunction with targeting inflammation, we

FGF2 decreased lesion size and apoptotic cell death more than MSCs

combined two inflammation-modulating treatments. Based on ear-

in glue alone. When a functional peptide derivative of BDNF was

lier studies in which we identified chemokine (C-C motif) ligand 20

incorporated in a self-assembling hydrogel scaffold prior to seeding

(CCL20) as being significantly elevated after TBI,135,136 we combined

with MSCs and activated astrocytes, the resulting structure was able

treatment with pioglitazone, a peroxisome proliferator-activated

to reduce TBI lesion size.154

receptor gamma agonist that inhibits CCL20, with treatment with
MSCs.88 The pioglitazone was administered once a day for 5 days
after TBI. On day 5, MSCs were administered intranasally. The com-
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bination of pioglitazone and MSCs was significantly better than either treatment alone on measures of anxiety, inflammation in the

Over the last two decades, there is a wealth of preclinical data,

brain, and endogenous NSC proliferation. A similar approach was

suggesting that MSCs may be an effective treatment, either alone

taken by Peruzzaro and associates when they engineered MSC's to

or in combination, to improve outcome after TBI. Clinical trials are

overexpress IL-10137 before transplantation in a TBI model.

still in the early stages. Even with an abundance of data, there are

Growth or trophic factor delivery in conjunction with cell admin-

still questions that should be addressed before these cells are rou-

istration is another approach that has been studied. These growth/

tinely used to treat TBI or other CNS injuries or disease. Perhaps,

trophic factors may favorably condition the environment in the TBI

most important is the issue of dosing. All studies in TBI to date have

brain, or they may protect the transplanted cells from cell death.

used a single dose of MSCs and doses used in the clinical studies

GDNF, epidermal growth factor, and VEGF have been shown to

have ranged from a total of 2.5 × 106 cells up to 12 × 106 cells per

protect the brain from neuronal injury and increase regeneration of

kilogram.124,125 Not only do different research groups use different

138-140

different cell types.

However, growth factor delivery can be

cell doses, in those studies using combination treatments, there is

problematic. Growth factors have very short half-lives, necessitating

no indication whether dosing of the cell and/or the pharmacologic

continual local delivery.141 Further, systemic delivery is often asso-

changes when the two are used in combination. To complicate is-

142

As a result, it is imperative to deliver the

sues further, patients may be taking a plethora of medications either

growth factors into the brain near the injury. Liu et al143 showed that

prophylactically (such as baby aspirin or statins) or to treat common

intracerebroventricular administration of fibroblast growth factor

chronic diseases (beta blockers). For example, aspirin altered the

2 (FGF2) for 7 days beginning at the time of MSC transplantation

immune and inflammatory profile of both endogenous monocytes

ciated with side effects.
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harvested from stroke patients or healthy controls and MSCs in cul155

ture.

after TBI and the mechanisms by which MSCs repair the brain and

When rats were treated with aspirin and cord blood-derived

improve functional outcomes, we are still years away from realiz-

MSCs singly or in combination, outcome tended to be somewhat

ing an effective regenerative medicine therapy for TBI that is widely

worse with the combination treatment.156 These considerations

available to patients.

are especially important as the population ages, since the elderly
are at risk for TBI and polypharmacy is an issue in this population.
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Another consideration with dosing is whether or not a single injection of cells is enough to maintain long-term improvements in the
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functional outcome. As mentioned previously, TBI is accompanied
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by chronic inflammation.
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As of yet, there are no studies in

rodent models of TBI that have examined repeated administration

ORCID

of MSCs. There are indications from small clinical studies in other
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neurologic diseases or injuries that may hint at the potential efficacy
of this dosing approach in TBI. For example, in patients with incomplete spinal cord injury, 30 × 106 cells were administered into the
subarachnoid space four times at three-month intervals

159

; while

improvements in function were noted, the improvements were different for each individual patient. Patients with amyotrophic lateral
sclerosis (ALS) were injected twice intrathecally with autologous
MSCs (1 × 106 cells/kg) 28 days apart and followed for 1 year.160
These patients had no severe adverse events and function as measured with the ALS Functional Rating Scale-Revised stabilized.
Another issue that needs to be addressed in this field is the reliance on rodents in the early testing of potential new therapeutics.
While using mice and rats is cost-effective and allows manipulation
of the genome, there are significant differences in the structure of
the rodent brain and the human brain, not only in size, but also in,
cerebrovascular volume, oxygen and glucose requirements, lissencephalic vs gyrencephalic architecture, and the amount of white
matter present.161 It is imperative that larger animal models are used
for the testing of new therapies including cell therapies so that we
can distinguish good candidate therapies that are likely to succeed in
clinical trials from those that will not. There has been some work in
the development and characterization of porcine and ovine models
of TBI, but there are currently no studies of MSC therapies and only
a handful of MSC-derive exosome studies108 in these larger animal
models TBI models.161,162

7 | S U M M A RY
The preclinical data on MSCs both alone and in conjunction with
other treatment strategies are promising. These cells have entered
at least Phase I (safety) clinical trials for multiple nervous system
diseases and injuries, most notably cerebral ischemia,163-166 multiple
sclerosis,167-174 Alzheimer's disease,175 and TBI.133,150,176 While we
have a better understanding of the pathologic cascades triggered
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